ArticleFrontiers in oncology2025
Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: JUNIPER, a randomized, phase III trial of patients with stage IV non-small cell lung cancer and a detectable Kristen rat sarcoma ( Materials and methods: Of the 453 patients enrolled in the JUNIPER trial, tumor specimens for biomarker analysis were available for 148 (abemaciclib arm, n=79; erlotinib arm, n=69). Samples were profiled for gene expression and classified into 3 previously identified expression subtypes (KL, KP, and K). Tumor response, OS, and PFS were assessed within each subtype. Results: Retrospective analyses of expression subtypes revealed an OS advantage for patients with KL subtype tumors who were receiving abemaciclib versus those with the KL subtype who were receiving erlotinib (median, 13.05 vs 5.65 months; hazard ratio, 0.25; 95% confidence interval, 0.09-0.73; Conclusions: Patients with KL expression subtype tumors may derive better OS and PFS from abemaciclib versus erlotinib in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.